STANDARD BIOTOOLS INC. — fact timeline

STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue in the range of approximately $94 million–$95 million. Guidance reaffirmed.

“For the full year, core product and service revenues are expected to be in the range of approximately $94 million–$95 million.”

STANDARD BIOTOOLS INC. reported the fourth quarter ended December 31, 2022 results: revenue in the range of $26 million–$27 million. Guidance reaffirmed.

“For the fourth quarter, core product and service revenues (Genomics and Proteomics excluding discontinued and COVID-19 related products) are expected to be in the range of $26 million–$27 million, representing approximately 4%–9% sequential quarterly growth.”

STANDARD BIOTOOLS INC. reported financial results for third quarter ended September 30, 2022.

“On November 8, 2022, Standard BioTools Inc. (the “Company”) issued a press release reporting its financial results for the third fiscal quarter of 2022.”

Nicholas Khadder resigned as Senior Vice President, General Counsel and Corporate Secretary at STANDARD BIOTOOLS INC..

“On June 30, 2022, Nicholas Khadder notified Standard BioTools Inc. (the “Company”) of his intention to resign from his position as Senior Vice President, General Counsel and Corporate Secretary, and from any and all other positions he holds as an officer or employee of the Company, in order to pursue another employment opportunity.”

Bradley Kreger departed as Senior Vice President, Global Operations at STANDARD BIOTOOLS INC..

“On June 22, 2022, Standard BioTools Inc. (the “Company”) and Bradley Kreger, Senior Vice President, Global Operations, agreed that, following a transition period, Mr. Kreger’s final day of employment by the Company would be October 3, 2022.”

Frank Witney was appointed as Director at STANDARD BIOTOOLS INC..

“the Board also appointed Dr. Frank Witney to the Board to serve as a Class III director”

Martin Madaus was appointed as Director at STANDARD BIOTOOLS INC..

“Viking has designated Martin Madaus as the Series B-2 Director and, accordingly, effective as of the Closing Date, the Board has appointed Dr. Madaus”

Eli Casdin was appointed as Director at STANDARD BIOTOOLS INC..

“Casdin has designated Eli Casdin as the Series B-1 Director and, accordingly, effective as of the Closing Date, the Board has appointed Mr. Casdin to serve as the Series B-1 Director”

Michael Egholm was appointed as Director at STANDARD BIOTOOLS INC..

“the Board also appointed Michael Egholm as a Class I director”

Nicolas M. Barthelemy resigned as Director at STANDARD BIOTOOLS INC..

“Stephen Christopher Linthwaite, Ana K. Stankovic and Nicolas M. Barthelemy each resigned from the Board”

Ana K. Stankovic resigned as Director at STANDARD BIOTOOLS INC..

“Stephen Christopher Linthwaite, Ana K. Stankovic and Nicolas M. Barthelemy each resigned from the Board”

Stephen Christopher Linthwaite resigned as Director at STANDARD BIOTOOLS INC..

“Stephen Christopher Linthwaite, Ana K. Stankovic and Nicolas M. Barthelemy each resigned from the Board”

Franklin R. Witney was appointed as Director at STANDARD BIOTOOLS INC..

“the Board appointed Franklin R. Witney to serve as a member of the Board”

Colin McCracken resigned as Chief Commercial Officer at STANDARD BIOTOOLS INC..

“On March 10, 2022, Colin McCracken, the Chief Commercial Officer of Fluidigm Corporation (the “Company”), notified the Company of his intention to resign, effective as of June 12, 2022, after assisting with the Company’s transition plan with respect to his role and responsibilities.”

Stephen Christopher Linthwaite resigned as President and Chief Executive Officer at STANDARD BIOTOOLS INC..

“Stephen Christopher Linthwaite, the Company’s President and Chief Executive Officer and a member of the Board, will resign on the terms described below.”